Nov. 24 at 10:12 AM
$LUCD &
$PAVM @oaksapollo is DESPERATELY trying to mislead you. The ONLY VALID comparison with LUCD is CSTL, Castle BioSciences.
CSTL with the 2005 acquisition of Previse bought for less than
$5M the John Hopkins version of LUCD's EsoGuard which LUCD bought from Case Western. EsoGuard and Pevise are the SAME.
CSTL focus is PRIMARILY on the Esophageal space with TissueCypher and now EndoSign which is what Previse calls their EsoGuard equivalent.
The sampling method and assay are very similar for both CSTL and LUCD
EXAS is for Colorectal cancer. Its sampling method is diffeent.
The reason why oaksapollo wants to mislead you is CSTL, which is PROFITABLE, has an ACTUAL 80% Gross Margin, has
$275M in the BANK is valed at LESS than 2X sales. So using that methodology LUCD should be worth around
$10M (which is too low BTW)
But claiming that a BILLION + Valuation is realistic fro a Company out of money Summer 2026, that loses
$50M+ per year, and has sales of
$5M is FAR MORE UNREALSITIC.
